183 related articles for article (PubMed ID: 22933031)
21. Effects of respiratory motion on passively scattered proton therapy versus intensity modulated photon therapy for stage III lung cancer: are proton plans more sensitive to breathing motion?
Matney J; Park PC; Bluett J; Chen YP; Liu W; Court LE; Liao Z; Li H; Mohan R
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):576-82. PubMed ID: 24074932
[TBL] [Abstract][Full Text] [Related]
22. Voxel-Level BED Corrected Dosimetric and Radiobiological Assessment of 2 Kinds of Hybrid Radiotherapy Planning Methods for Stage III NSCLC.
Wang H; Huang Y; Chen H; Shao Y; Duan Y; Feng A; Gu H; Ma X; Xu Z; Kong Q; Zhou Y
Technol Cancer Res Treat; 2022; 21():15330338221107966. PubMed ID: 35731648
[No Abstract] [Full Text] [Related]
23. Effective avoidance of a functional spect-perfused lung using intensity modulated radiotherapy (IMRT) for non-small cell lung cancer (NSCLC): an update of a planning study.
Lavrenkov K; Singh S; Christian JA; Partridge M; Nioutsikou E; Cook G; Bedford JL; Brada M
Radiother Oncol; 2009 Jun; 91(3):349-52. PubMed ID: 18995919
[TBL] [Abstract][Full Text] [Related]
24. Dose-escalation by hypofractionated simultaneous integrated boost IMRT in unresectable stage III non-small-cell lung cancer.
Zhang Q; Cai XW; Feng W; Yu W; Fu XL
BMC Cancer; 2022 Jan; 22(1):96. PubMed ID: 35065627
[TBL] [Abstract][Full Text] [Related]
25. Importance of protocol target definition on the ability to spare normal tissue: an IMRT and 3D-CRT planning comparison for intraorbital tumors.
Hein PA; Gladstone DJ; Bellerive MR; Hug EB
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1540-8. PubMed ID: 16029816
[TBL] [Abstract][Full Text] [Related]
26. Intensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalation.
Kam MK; Chau RM; Suen J; Choi PH; Teo PM
Int J Radiat Oncol Biol Phys; 2003 May; 56(1):145-57. PubMed ID: 12694833
[TBL] [Abstract][Full Text] [Related]
27. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study.
Jeter MD; Gomez D; Nguyen QN; Komaki R; Zhang X; Zhu X; O'Reilly M; Fossella FV; Xu T; Wei X; Wang H; Yang W; Tsao A; Mohan R; Liao Z
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):730-737. PubMed ID: 29248169
[TBL] [Abstract][Full Text] [Related]
28. Lung sparing and dose escalation in a robust-inspired IMRT planning method for lung radiotherapy that accounts for intrafraction motion.
McCann C; Purdie T; Hope A; Bezjak A; Bissonnette JP
Med Phys; 2013 Jun; 40(6):061705. PubMed ID: 23718584
[TBL] [Abstract][Full Text] [Related]
29. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
Yom SS; Liao Z; Liu HH; Tucker SL; Hu CS; Wei X; Wang X; Wang S; Mohan R; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2007 May; 68(1):94-102. PubMed ID: 17321067
[TBL] [Abstract][Full Text] [Related]
30. Treating locally advanced lung cancer with a 1.5T MR-Linac - Effects of the magnetic field and irradiation geometry on conventionally fractionated and isotoxic dose-escalated radiotherapy.
Bainbridge HE; Menten MJ; Fast MF; Nill S; Oelfke U; McDonald F
Radiother Oncol; 2017 Nov; 125(2):280-285. PubMed ID: 28987747
[TBL] [Abstract][Full Text] [Related]
31. Adaptive intensity-modulated radiotherapy with simultaneous integrated boost for stage III non-small cell lung cancer: Is a routine adaptation beneficial?
Meng Y; Luo W; Xu H; Wang W; Zhou S; Tang X; Li Z; Zhou C; Yang H
Radiother Oncol; 2021 May; 158():118-124. PubMed ID: 33636232
[TBL] [Abstract][Full Text] [Related]
32. Assessment of different IMRT boost delivery methods on target coverage and normal-tissue sparing.
Dogan N; King S; Emami B; Mohideen N; Mirkovic N; Leybovich LB; Sethi A
Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1480-91. PubMed ID: 14630288
[TBL] [Abstract][Full Text] [Related]
33. A clinical study of shrinking field radiation therapy based on (18)F-FDG PET/CT for stage III non-small cell lung cancer.
Ding X; Li H; Wang Z; Huang W; Li B; Zang R; Sun H; Yi Y
Technol Cancer Res Treat; 2013 Jun; 12(3):251-7. PubMed ID: 23289475
[TBL] [Abstract][Full Text] [Related]
34. An assessment of cone beam CT in the adaptive radiotherapy planning process for non-small-cell lung cancer patients.
Duffton A; Harrow S; Lamb C; McJury M
Br J Radiol; 2016 Jun; 89(1062):20150492. PubMed ID: 27052681
[TBL] [Abstract][Full Text] [Related]
35. Potential for radiation therapy technology innovations to permit dose escalation for non-small-cell lung cancer.
Manon RR; Jaradat H; Patel R; Zhang T; Fenwick J; Tome W; Fowler J; Paliwal B; Soisson E; Yuan Z; Mehta M
Clin Lung Cancer; 2005 Sep; 7(2):107-13. PubMed ID: 16179097
[TBL] [Abstract][Full Text] [Related]
36. Superiority of conventional intensity-modulated radiotherapy over helical tomotherapy in locally advanced non-small cell lung cancer. A comparative plan analysis.
Song C; Pyo H; Kim J; Lim YK; Kim WC; Kim HJ; Kim DW; Cho KH
Strahlenther Onkol; 2012 Oct; 188(10):901-9. PubMed ID: 22895625
[TBL] [Abstract][Full Text] [Related]
37. Adaptive Dose Escalation using Serial Four-dimensional Positron Emission Tomography/Computed Tomography Scans during Radiotherapy for Locally Advanced Non-small Cell Lung Cancer.
Yap ML; Sun A; Higgins J; Clarke K; Marshall A; Becker N; Le LW; Vines DC; Bezjak A; Bissonnette JP
Clin Oncol (R Coll Radiol); 2016 Dec; 28(12):e199-e205. PubMed ID: 27637725
[TBL] [Abstract][Full Text] [Related]
38. Critical dose and toxicity index of organs at risk in radiotherapy: analyzing the calculated effects of modified dose fractionation in non-small cell lung cancer.
Pedicini P; Strigari L; Benassi M; Caivano R; Fiorentino A; Nappi A; Salvatore M; Storto G
Med Dosim; 2014; 39(1):23-30. PubMed ID: 24239409
[TBL] [Abstract][Full Text] [Related]
39. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy.
Liao ZX; Komaki RR; Thames HD; Liu HH; Tucker SL; Mohan R; Martel MK; Wei X; Yang K; Kim ES; Blumenschein G; Hong WK; Cox JD
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):775-81. PubMed ID: 19515503
[TBL] [Abstract][Full Text] [Related]
40. Fully automated VMAT treatment planning for advanced-stage NSCLC patients.
Della Gala G; Dirkx MLP; Hoekstra N; Fransen D; Lanconelli N; van de Pol M; Heijmen BJM; Petit SF
Strahlenther Onkol; 2017 May; 193(5):402-409. PubMed ID: 28314877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
